Achilles Therapeutics’ mission is to develop next-generation, patient-specific therapies that harness the immune system to destroy cancer cells. The therapies will target truncal (also known as clonal) tumour neo-antigens, unique flags to the immune system present on the surface of every cancer cell. These truncal neo-antigens are created early in the cancer’s evolution and present on all cancer cells in an individual patient’s tumour but not on healthy cells, so could allow scientists to target and destroy tumours without harming healthy tissues.
Achilles Therapeutics brings together four scientific Founders with world leading expertise in the understanding of cancer evolution, bioinformatics and the development of immunotherapies.
Achilles Therapeutics brings together four scientific Founders with world leading expertise in the understanding of cancer evolution, bioinformatics and the development of immunotherapies.
Location: United Kingdom, England, London
Employees: 201-500
Total raised: $437.09M
Founded date: 2016
Investors 6
| Date | Name | Website |
| - | Forbion | forbion.co... |
| - | RA Capital... | racap.com |
| - | Albion Cap... | albion.cap... |
| - | Perceptive... | perceptive... |
| - | Syncona Pa... | synconaltd... |
| - | UCL Techno... | ucltf.co.u... |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 31.03.2021 | - | $175M | - |
| 20.11.2020 | Series C | $69.81M | - |
| 03.09.2019 | Series B | $122.46M | - |
Mentions in press and media 15
| Date | Title | Description |
| 10.09.2024 | NanoSyrinx: A New Dawn in Biotech with £10 Million Funding | In the world of biotechnology, innovation is the lifeblood. Today, a new player is making waves. NanoSyrinx, a synthetic biology company based in Coventry, UK, has successfully raised approximately £10 million (around $13 million) in a rece... |
| 10.09.2024 | NanoSyrinx closes c. £10 million GBP financing and appoints Dr. Edwin Moses as Chairman | Round co-led by BGF, Octopus Ventures and M Ventures, with support from new corporate investor, Eli Lilly and Company, and existing investors, IQ Capital and Meltwind Appointment of Edwin Moses as Chairman to support the leadership team in ... |
| 10.09.2024 | NanoSyrinx Closes Approx. £10M Financing | NanoSyrinx, a Coventry, UK-based synthetic biology company, raised approx. £10M in funding. The round was led by BGF, Octopus Ventures and M Ventures, with participation from new corporate investor, Eli Lilly and Company, and existing inves... |
| 11.05.2023 | Achilles Therapeutics’ New Immunogenicity Prediction Application of its AI-Powered PELEUS Platform Uniquely Identifies the Most Potent T Cell Antigens | – New AI module delivers a “Target-to-T cell” approach for revolutionizing the identification and prioritization of targets for personalized antigen approaches – Achilles Therapeutics plc, a clinical-stage biopharmaceutical company developi... |
| 07.02.2023 | Investor Syncona blames bear market's ravaging of British biotechs for 'disappointing' returns | Life sciences investment firm Syncona has blamed a “disappointing” drop in returns on plummeting share prices for British biotechs across its portfolio in December. The London-based company ended 2022 with net assets of £1.29 billion ($1.55... |
| 19.12.2022 | Achilles Therapeutics presents encouraging Phase I/IIa update on clonal neoantigen reactive T cells in advanced NSCLC and melanoma | |
| 31.03.2021 | Achilles Therapeutics Announces Pricing of Initial Public Offering | |
| 31.03.2021 | Achilles Therapeutics’ IPO nabs $175M to bring cell therapies to solid tumors | A different type of cell therapy called tumor infiltrating lymphocytes (TIL) could offer yet another alternative, plus the potential to address solid tumors. Several biotechs have TILs in clinical development. Achilles Therapeutics aims to ... |
| 19.11.2020 | SYNCONA LIMITED Syncona : Achilles Therapeutics Raises £52.7 Million in an Oversubscribed Series C Financing to Further Advance the Development of Personalised T cell Therapies to Treat Solid Tumours... | Achilles Therapeutics ('Achilles'), a clinical-stage biopharmaceutical company developing personalised T cell therapies targeting clonal neoantigens, a novel class of tumour target, today announced it has raised £52.7 million in an oversubs... |
| 19.11.2020 | Syncona : Achilles Therapeutics Raises £52.7 Million in an Oversubscribed Series C Financing to Further Advance the Development of Personalised T cell Therapies to Treat Solid Tumours | Achilles Therapeutics ('Achilles'), a clinical-stage biopharmaceutical company developing personalised T cell therapies targeting clonal neoantigens, a novel class of tumour target, today announced it has raised £52.7 million in an oversubs... |
Show more